Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia.

Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children’s Oncology Group AAML1331 Trial – JAMA Oncology

News release: Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy – NIH News Releases

Commentary on Twitter

Clinical trial showed that pediatric patients with acute promyelocytic leukemia (APL) have very high cure rates with treatment regimen that uses targeted therapy and no cytotoxic chemotherapy for standard risk APL or limited anthracycline for high risk APL https://t.co/V3mahhIb6Y

— JAMA Oncology (@JAMAOnc) November 11, 2021